PIA
IGC icon

Powell Investment Advisors’s IGC Pharma IGC Stock Holding History

Powell Investment Advisors’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-25,000
Closed -$26K – 115
2020
Q3 		$26K Buy
+25,000
New +$25.4K 0.02% 111

Other funds holding IGC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFA
Carroll Financial Associates Charlotte, North Carolina $1.88B AUM 20.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DP
Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Powell Investment Advisors's IGC Position: Q4 2020 in Review

Powell Investment Advisors sold out of IGC Pharma (IGC) in Q4 2020, closing a stake of 25,000 shares — an estimated $26K sold.

Powell Investment Advisors first reported a position in IGC in Q3 2020 and held it in 1 quarter. The position peaked at $26K in Q3 2020. 25 funds tracked by Wall St. Rank hold IGC as of Q4 2020.

  • Powell Investment Advisors reported no remaining IGC Pharma position as of Q4 2020 after selling out during the quarter.
  • Powell Investment Advisors sold 25,000 IGC Pharma shares in Q4 2020, an estimated $26K.
  • Powell Investment Advisors first reported a position in IGC Pharma in Q3 2020 and held it in 1 quarter.
  • Powell Investment Advisors's IGC Pharma position peaked at $26K in Q3 2020.
  • 25 funds tracked by Wall St. Rank held IGC Pharma as of Q4 2020.

Based on Powell Investment Advisors's 13F filing for Q4 2020, filed 14 Jan 2021.